🇺🇸 Vaginal Progesterone in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Abortion — 1 report (10%)
2. Alanine Aminotransferase Increased — 1 report (10%)
3. Anxiety — 1 report (10%)
4. Application Site Erythema — 1 report (10%)
5. Application Site Pain — 1 report (10%)
6. Application Site Vesicles — 1 report (10%)
7. Aspartate Aminotransferase Increased — 1 report (10%)
8. Depression — 1 report (10%)
9. Impaired Work Ability — 1 report (10%)
10. Inappropriate Schedule Of Product Administration — 1 report (10%)

Source database →

Frequently asked questions

Is Vaginal Progesterone approved in United States?

Vaginal Progesterone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Vaginal Progesterone in United States?

University of North Carolina, Chapel Hill is the originator. The local marketing authorisation holder may differ — check the official source linked above.